Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Enoxaparin vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.
Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement, knee replacement, or medical patients at risk,Treatment of acute DVT with or without pulmonary embolism,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) in combination with aspirin,Prophylaxis of ischemic complications in patients with acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
Management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate,Off-label: acute pain, chronic pain
1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.
1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Terminal elimination half-life is 4.5 hours after a single subcutaneous dose, and 7 hours after repeated dosing, reflecting accumulation. Mean half-life is approximately 4-5 hours in healthy volunteers.
Acetaminophen: 2-3 hours (normal), prolonged in hepatic impairment. Caffeine: 3-6 hours (adults), prolonged in liver disease or with oral contraceptives. Dihydrocodeine: 3.5-6 hours (terminal). Clinical context: q6h dosing interval appropriate; accumulation risk in renal/hepatic impairment.
Enoxaparin is primarily metabolized in the liver by desulfation and depolymerization; elimination is via renal excretion of low molecular weight fragments.
Acetaminophen: primarily hepatic via glucuronidation and sulfation; minor CYP2E1, CYP1A2, CYP3A4. Caffeine: hepatic via CYP1A2. Dihydrocodeine: O-demethylation to dihydromorphine via CYP2D6; also via CYP3A4.
Renal elimination accounts for 40% of the administered dose, with the remainder undergoing hepatic metabolism and/or distribution. Biliary/fecal excretion is minimal (<5%).
Acetaminophen: renal excretion of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%), <5% unchanged. Caffeine: renal excretion of metabolites (1-methyluric acid, 1-methylxanthine, etc.), <2% unchanged. Dihydrocodeine: renal excretion of metabolites (dihydrocodeine-6-glucuronide, nordihydrocodeine, dihydromorphine), ~20% unchanged. Overall, predominantly renal (≥85%), minor biliary/fecal.
Enoxaparin is highly protein bound (>80%) to antithrombin III and other plasma proteins.
Acetaminophen: 10-25% (albumin). Caffeine: 25-36% (albumin). Dihydrocodeine: ~20-30% (albumin and α1-acid glycoprotein).
Volume of distribution is approximately 0.15-0.25 L/kg (4-6 L total), indicating limited extravascular distribution, primarily confined to the vascular compartment.
Acetaminophen: 0.7-1.0 L/kg. Caffeine: 0.5-0.8 L/kg. Dihydrocodeine: 1.0-1.5 L/kg. Clinical meaning: moderate distribution, potential for central nervous system penetration.
Subcutaneous: Approximately 92-100% bioavailability based on anti-Xa activity. Oral: negligible due to poor absorption.
Acetaminophen: oral 75-85%. Caffeine: oral ~100%. Dihydrocodeine: oral ~20-30% (first-pass metabolism; extended-release formulations have altered bioavailability).
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily for treatment; for prophylaxis, reduce to 30 mg subcutaneously once daily.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-30 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; avoid in severe impairment due to dihydrocodeine accumulation.
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C: avoid use due to acetaminophen hepatotoxicity and dihydrocodeine accumulation.
For treatment of venous thromboembolism: 1 mg/kg subcutaneously every 12 hours. For prophylaxis: 0.5 mg/kg subcutaneously every 12 hours. Dose adjustments based on anti-Xa monitoring.
Not recommended for children under 12 years due to dihydrocodeine risks; for adolescents 12-18 years: 1 tablet orally every 4-6 hours as needed, maximum 4 tablets per day (weight-based dosing not established).
Increased risk of bleeding; consider lower initial doses and monitor renal function and bleeding closely. No specific dose adjustment solely based on age.
Initiate with 1 tablet orally every 6 hours; caution due to increased sensitivity to opioids and hepatotoxicity from acetaminophen; maximum 4 tablets per day; monitor renal and hepatic function.
Spinal or epidural hematomas, including subsequent paralysis, may occur in patients receiving enoxaparin who are undergoing neuraxial anesthesia or spinal puncture. Risk is increased by use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis, history of traumatic or repeated epidural or spinal puncture, or spinal deformity.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen can cause fatal hepatotoxicity; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Increased risk of bleeding, especially in patients with renal impairment, uncontrolled hypertension, or history of gastrointestinal bleeding; thrombocytopenia (including heparin-induced thrombocytopenia); elevated serum potassium levels (hyperkalemia); use in pregnancy and lactation; elderly patients (increased bleeding risk).
Addiction, abuse, and misuse; respiratory depression; acetaminophen hepatotoxicity; drug interaction with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; risk of serotonin syndrome; severe hypotension; adrenal insufficiency; use in patients with head injury or increased intracranial pressure; seizures; avoid in patients with severe hepatic impairment.
Active major bleeding; history of heparin-induced thrombocytopenia (HIT); hypersensitivity to enoxaparin or heparin; patients undergoing regional anesthesia with known bleeding risk; severe uncontrolled hypertension; bacterial endocarditis; conditions with increased risk of hemorrhage (e.g., recent surgery, trauma, peptic ulcer disease, hemorrhagic stroke).
Hypersensitivity to any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; concomitant use with MAOIs or within 14 days; severe hepatic impairment.
No specific food interactions. Vitamin K-rich foods (leafy greens) do not significantly affect LMWH, in contrast to warfarin. Avoid excessive alcohol intake due to increased bleeding risk. Do not take supplements like fish oil, ginkgo, or ginger without consulting prescriber due to antiplatelet effects.
Avoid alcohol; may increase risk of hepatotoxicity and CNS depression. High-fat meals may delay absorption but do not significantly affect overall exposure. Caffeine-containing foods and beverages may increase stimulant effects.
Enoxaparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations has been observed in human studies. First trimester: no known risk. Second and third trimesters: no known risk, though there is a risk of maternal hemorrhage that could affect the fetus.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data on malformations. Dihydrocodeine: Opioid; first trimester: increased risk of neural tube defects (OR 2.0-2.5); third trimester: risk of neonatal opioid withdrawal syndrome (NOWS). Overall, combination product should be used only if benefit outweighs risks.
Enoxaparin is not detected in breast milk due to its high molecular weight and protein binding; therefore, it is considered compatible with breastfeeding. M/P ratio: not applicable (not measurable).
Acetaminophen: Excreted in breast milk (M/P ratio ~0.9); safe at therapeutic doses. Caffeine: Excreted (M/P ~0.5-0.8); moderate intake (<300 mg/day) generally safe. Dihydrocodeine: Excreted in low levels; however, interindividual variability in metabolism (CYP2D6) may lead to higher morphine concentrations in some infants; risk of neonatal respiratory depression. M/P ratio not well established for dihydrocodeine. Use with caution, monitor infant for sedation and feeding difficulties.
Pregnancy increases clearance of enoxaparin; dose adjustments may be needed based on anti-Xa monitoring. Generally, dose adjustments are not routinely required for standard prophylactic doses, but therapeutic doses may need to be increased (e.g., weight-based dosing) and monitored. Avoid use in patients with active major bleeding or known hypersensitivity.
No specific dose adjustments for pregnancy due to lack of pharmacokinetic studies for this combination. However, note: Increased clearance of acetaminophen in pregnancy may require higher doses for analgesia but remains within standard limits. Caffeine clearance decreases in third trimester; consider reducing intake to <200 mg/day. Dihydrocodeine: Increased volume of distribution and clearance in pregnancy; dose may need titration but no established guidelines. Use lowest effective dose for shortest duration.
Enoxaparin is a low molecular weight heparin (LMWH) that preferentially inhibits factor Xa over thrombin. Monitor anti-factor Xa levels in patients with renal impairment (Cr Cl <30 m L/min) and in pregnant women. Protamine sulfate partially reverses anticoagulation (approximately 60% anti-factor Xa activity). Avoid intramuscular injections due to hematoma risk. Epidural/spinal anesthesia increases risk of spinal hematoma; remove catheter at least 12 hours after last dose (or 24 hours if therapeutic dosing). Adjust dose for moderate renal impairment (Cr Cl 30-50 m L/min) in treatment of VTE or unstable angina.
Dihydrocodeine is a prodrug requiring CYP2D6 metabolism to active metabolites; poor metabolizers may have reduced efficacy while ultrarapid metabolizers risk toxicity. Caffeine potentiates analgesia and may cause insomnia with evening use. Do not exceed 8 tablets per 24 hours due to acetaminophen hepatotoxicity risk. Use with caution in elderly and patients with renal impairment.
Do not skip doses; take at the same time each day.,Rotate injection sites (left and right sides of abdomen) and do not rub the site after injection.,Watch for signs of bleeding: unusual bruising, blood in urine/stool, prolonged bleeding from cuts, or bleeding from gums.,Seek emergency care if you have signs of a spinal blood clot (back pain, numbness/weakness in legs, loss of bowel or bladder control).,Avoid aspirin, NSAIDs (ibuprofen, naproxen), and other blood thinners unless prescribed by your doctor.,Tell all healthcare providers including dentists that you are taking enoxaparin.,Do not drive or operate heavy machinery if you feel dizzy or weak from bleeding.,Store enoxaparin at room temperature; do not freeze.
Take with food if stomach upset occurs.,Avoid alcohol and products containing acetaminophen to prevent liver damage.,Do not exceed 8 tablets in 24 hours.,May cause drowsiness; avoid driving or operating machinery until you know how this medication affects you.,If you have a history of drug dependence, use with caution as dihydrocodeine can be habit-forming.
No interactions on record
"The combination of chlordiazepoxide, a benzodiazepine that enhances GABAergic inhibition, and dihydrocodeine, an opioid agonist primarily at mu-receptors, results in additive central nervous system (CNS) depression. This synergy increases the risk of profound sedation, respiratory depression, coma, and death, particularly in vulnerable populations such as the elderly or those with pre-existing respiratory compromise. Concurrent use also elevates the potential for hypotension and psychomotor impairment, leading to falls or accidents."
"Reserpine depletes catecholamines in the central nervous system and peripheral adrenergic neurons, leading to reduced sympathetic outflow. Dihydrocodeine, an opioid agonist, can cause further central nervous system depression and hypotension. When combined, there is an additive risk of excessive hypotension, bradycardia, and profound sedation, potentially leading to falls or respiratory depression."
"Dihydrocodeine, an opioid analgesic, undergoes O-demethylation primarily via CYP2D6 to form dihydromorphine, which contributes to its analgesic effects. Clemastine, a first-generation antihistamine, is metabolized mainly by CYP2D6 as well. When co-administered, clemastine competitively inhibits CYP2D6, reducing the clearance of dihydrocodeine and decreasing the formation of the active metabolite dihydromorphine. This can lead to diminished analgesic efficacy and potentially increased levels of parent dihydrocodeine, heightening the risk of opioid-related adverse effects such as respiratory depression, sedation, and constipation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Enoxaparin vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, answered by our medical review team.
Enoxaparin is a Low Molecular Weight Heparin that works by Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is a Opioid Agonist that works by Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Enoxaparin and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Enoxaparin is: 1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.. The standard adult dose of ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is: 1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Enoxaparin and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Enoxaparin is classified as Category A/B. Enoxaparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations has been observed in human studies. First trimester: no known risk. Second a. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.